Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Children's Mercy Hospital
mi
from
Kansas City, MO
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Children's Hospital New York-Presbyterian
mi
from
New York, NY
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
New York University Medical Center
mi
from
New York, NY
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Nationwide Children's Hospital
mi
from
Columbus, OH
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Oregon Health and Science University
mi
from
Portland, OR
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
St. Jude
mi
from
Memphis, TN
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
St. Jude
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Vanderbilt Children's Hospital
mi
from
Nashville, TN
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Cook Childrens Medical Center
mi
from
Forth Worth, TX
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Cook Childrens Medical Center
mi
from
Forth Worth, TX
Click here to add this to my saved trials
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  1/31/2014
Seattle Children's Hospital
mi
from
Seattle, WA
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 1/31/2014
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects
Status: Enrolling
Updated:  2/3/2014
Parexel International Early Development Clinical Units
mi
from
Glendale, CA
A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects
Status: Enrolling
Updated: 2/3/2014
Parexel International Early Development Clinical Units
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
Status: Enrolling
Updated:  2/10/2014
Children's Hospital Oakland
mi
from
Oakland, CA
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
Status: Enrolling
Updated: 2/10/2014
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
Status: Enrolling
Updated:  2/10/2014
Children's Hospital - Boston
mi
from
Boston, MA
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
Status: Enrolling
Updated: 2/10/2014
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
Status: Enrolling
Updated:  2/10/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
Status: Enrolling
Updated: 2/10/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
The University of California Irvine
mi
from
Orange, CA
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Norwalk Hospital
mi
from
Norwalk, CT
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Norwalk Hospital
mi
from
Norwalk, CT
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
University of Maryland Medical Center
mi
from
Baltimore, MD
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Boston Med Ctr
mi
from
Boston, MA
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Hoboken Universtiy Medical Center
mi
from
Hoboken, NJ
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Hoboken Universtiy Medical Center
mi
from
Hoboken, NJ
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Columbia University Medical Center
mi
from
New York, NY
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Universtiy of North Carloina at Chapel Hill
mi
from
Chapel Hill, NC
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Universtiy of North Carloina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Lancaster Reginal Medical Center
mi
from
Lancaster, PA
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Lancaster Reginal Medical Center
mi
from
Lancaster, PA
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Rhode Island Hospital
mi
from
Providence, RI
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated:  3/12/2014
Baylor University
mi
from
Dallas, TX
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)
Status: Enrolling
Updated: 3/12/2014
Baylor University
mi
from
Dallas, TX
Click here to add this to my saved trials
Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Effect of ADP Blocking Drugs on Platelet Aggregation on the AggreGuide A-100 Instrument
Status: Enrolling
Updated:  4/10/2014
Juno Research
mi
from
Houston, TX
Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Effect of ADP Blocking Drugs on Platelet Aggregation on the AggreGuide A-100 Instrument
Status: Enrolling
Updated: 4/10/2014
Juno Research
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Arizona Center for Cancer Care
mi
from
Glendale, AZ
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Arizona Center for Cancer Care
mi
from
Glendale, AZ
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Desert Springs Cancer Care
mi
from
Scottdale, AZ
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Desert Springs Cancer Care
mi
from
Scottdale, AZ
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Innovative Clinical Research Institute
mi
from
Burbank, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Innovative Clinical Research Institute
mi
from
Burbank, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Beaver Medical Group
mi
from
Highland, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Beaver Medical Group
mi
from
Highland, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Los Angeles, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
California Cancer Associates for Research and Excellence
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
North County Oncology
mi
from
Oceanside, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
North County Oncology
mi
from
Oceanside, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Hematology Oncology Medical Group
mi
from
Orange, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Hematology Oncology Medical Group
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Sarcoma Oncology
mi
from
Santa Monica, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Sarcoma Oncology
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Northeast Georgia Cancer Care
mi
from
Athens, GA
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Kentucky Cancer Clinic
mi
from
Hazard, KY
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Kentucky Cancer Clinic
mi
from
Hazard, KY
Click here to add this to my saved trials
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated:  4/15/2014
Saint Louis University
mi
from
St. Louis, MO
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Status: Enrolling
Updated: 4/15/2014
Saint Louis University
mi
from
St. Louis, MO
Click here to add this to my saved trials